A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,575

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv270 · Cited by 738

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430

Non–Small Cell Lung Cancer, Version 4.2024

Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 945

EGFR signaling pathway as therapeutic target in human cancers

Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 390

AKT and ERK dual inhibitors: The way forward?

Cao, Z., Liao, Q., Su, M., Huang, K., Jin, J., & Cao, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.025 · Cited by 244

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., Bazhenova, L. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1598 · Cited by 231

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Passaro, A., Mok, T. S. K., Peters, S., Popat, S., Ahn, M., & de Marinis, F. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.002 · Cited by 219

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Passaro, A., Leighl, N. B., Blackhall, F. H., Popat, S., Kerr, K. M., Ahn, M., Arcila, M. E., Arrieta, O. G., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 209

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 202

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations

Shah, R. N. H., & Lester, J. F. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.003 · Cited by 183

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment

Zhang, T., Wan, B., Zhao, Y., Li, C., Liu, H., Lv, T., Zhan, P., & Song, Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.12 · Cited by 163

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Gray, J. E., Okamoto, I., Sriuranpong, V., Vansteenkiste, J., Imamura, F., Lee, J. S., Pang, Y., Cobo, M., Kasahara, K., Cheng, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1126 · Cited by 130

Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer

Wen, S., Dai, L., Wang, L., Wang, W., Wu, D., Wang, K., He, Z., Wang, A., Chen, H., Zhang, P., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0572 · Cited by 131

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 130

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

Fang, W., Huang, Y., Hong, S., Zhang, Z., Wang, M., Gan, J., Wang, W., Guo, H., Wang, K., & Zhang, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5820-0 · Cited by 120

Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic Sequencing

Kohsaka, S., Petronczki, M. P., Solca, F., & Maemondo, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0736 · Cited by 123

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

Yang, G., Li, J., Xu, H., Yang, Y., Yang, L., Xu, F., Xia, B., Zhu, V. W., Nagasaka, M., Yang, Y., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.014 · Cited by 114

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

Yamada, T., Hirai, S., Katayama, Y., Yoshimura, A., Shiotsu, S., Watanabe, S., Kikuchi, T., Hirose, K., Kubota, Y., Chihara, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2037 · Cited by 110

Detection of circulating tumor DNA from non‐small cell lung cancer brain metastasis in cerebrospinal fluid samples

Ma, C., Yang, X., Xing, W., Yu, H., Si, T., & Guo, Z. R. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13300 · Cited by 92

Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review

Burnett, H. F., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P. J., & Li, T. M. W. Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247620 · Cited by 91

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy

Chen, K., Cheng, G., Zhang, F., Zhu, G., Xu, Y., Yu, X., Huang, Z., & Fan, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.010 · Cited by 89

Clinical relevance of PD-L1 expression and CD8 T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

Liu, S.-Y., Dong, Z.-Y., Wu, S.-P., Xie, Z., Yan, L.-X., Li, Y.-F., Yan, H.-H., Su, J., Yang, J.-J., Zhou, Q., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.010 · Cited by 85

Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis

Liu, H., Zhang, B., & Sun, Z. (2020) · 癌症：英文版 · doi:10.1002/cac2.12005 · Cited by 91

An up-to-date overview of computational polypharmacology in modern drug discovery

Chaudhari, R. R., Fong, L. W. R., Tan, Z., Huang, B., & Zhang, S. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1767063 · Cited by 84

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer

Melosky, B. L., Wheatley‐Price, P., Juergens, R. A., Sacher, A. G., Leighl, N. B., Tsao, M., Cheema, P. K., Snow, S. L., Liu, G., Card, P. B., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.002 · Cited by 75

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

Garinet, S., Laurent‐Puig, P., Blons, H., & Oudart, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060144 · Cited by 71

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Liu, S. M., Sun, H., Zhou, J., Jie, G., Xie, Z., Shao, Y. W., Zhang, X., Ye, J., Chen, C., Zhang, X., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-00199-z · Cited by 71

A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer

Lin, T. Y., Fu, Y., Zhang, X., Gu, J., Ma, X., Miao, R., Xiang, X., Niu, W., Qu, K., Liu, C., et al. (2018) · Aging · doi:10.18632/aging.101550 · Cited by 63

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)

Cardona, A. F., Rojas, L., Zatarain-Barrón, Z. L., Freitas, H., Granados, S. T., Castillo, O., Oblitas, G., Corrales, L., Castro, C. D., Ruíz-Patiño, A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.007 · Cited by 62

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

Attili, I., Passaro, A., Pisapia, P., Malapelle, U., & de Marinis, F. (2022) · Current Oncology · doi:10.3390/curroncol29010024 · Cited by 63

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions

Chen, K., Pan, G., Cheng, G., Zhang, F., Xu, Y., Huang, Z., & Fan, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13748 · Cited by 59

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon, S., Kim, Y., Lim, S. W., Cho, J. H., Park, S., Lee, J., Sun, J., Choi, Y., Lee, S., Ahn, J. S., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.151 · Cited by 56

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.005 · Cited by 54

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer ( NSCLC )

Qin, Q., Li, X., Liang, X., Zeng, L., Wang, J., Sun, L., & Zhong, D. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13521 · Cited by 55

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations

Yang, G., Li, J., Xu, H., Sun, Y., Liu, L., Li, H., Yang, L., Zhang, Y., Li, G., & Wang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.027 · Cited by 51

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Floc’h, N., Lim, S., Bickerton, S., Ahmed, A., Orme, J. P., Urosevic, J., Martin, M. J., Cross, D. A. E., Cho, B. C., & Smith, P. D. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0103 · Cited by 48

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer

Evrard, S., Clermont, E., Rouquette, I., Murray, S. J., Dintner, S., Nam‐Apostolopoulos, Y., Bellosillo, B., Varela, M., Nadal, E., Wiedorn, K. H., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.010 · Cited by 49

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis

Kate, S., Chougule, A., Joshi, A., Noronha, V., Patil, V., Dusane, R., Solanki, L., Tiwrekar, P., Trivedi, V., & Prabhash, K. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s181406 · Cited by 45

EGFR exon 20 insertion mutations in non-small cell lung cancer

Wang, F., Li, C., Wu, Q., & Lu, H. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.10 · Cited by 40

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study

on behalf of AME Lung Cancer Collaborative Group, Xu, C., Wang, W., Wang, D., Wang, Q., Pu, X., Zhu, Y., Huang, J., Yu, Z., Cui, Z., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-382 · Cited by 40

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

Kujtan, L. A., & Subramanian, J. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1596030 · Cited by 43

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need

Pretelli, G., Spagnolo, C. C., Ciappina, G., Santarpía, M., & Pasello, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108878 · Cited by 39

Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors

Chang, L.-C., Lim, C., Chang, L., Chen, K., Shih, J., & Yu, C. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.025 · Cited by 35

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression

Liu, W., Zhuang, C., Huang, T., Yang, S., Zhang, M., Lin, B., & Jiang, Y. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1521 · Cited by 29

Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory

Mao, L., Zhao, W., Li, X., Zhang, S., Zhou, C., Zhou, D., Ou, X., Xu, Y., Tang, Y., Ou, X., et al. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.602726 · Cited by 32

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer

Seo, D., & Lim, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115917 · Cited by 28

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation

Wu, S., Yu, C., Yang, J. C., & Shih, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920946156 · Cited by 27

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02053-2 · Cited by 30

Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with EGFR G719X / L861Q / S768I

Pang, L., Gan, J., Tan, J., Huang, Y., Liao, J., Liang, W., Deng, P., & Fang, W. (2022) · Cancer · doi:10.1002/cncr.34451 · Cited by 26

Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC

Yang, S., Mao, S., Li, X., Zhao, C., Liu, Q., Yu, X., Wang, Y., Liu, Y., Pan, Y., Wang, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.018 · Cited by 26

Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer

Melosky, B. L., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Liu, G., & Cheema, P. K. (2020) · Current Oncology · doi:10.3747/co.27.6007 · Cited by 27

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

Li, T., Wang, S., Ying, J., Wang, Y., Hu, X., Hao, X., Xu, Z., Xing, P., & Li, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14156 · Cited by 22

The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

Li, M., Zhou, C., Yang, J., Lü, S., Zheng, D., Hu, J., Zeng, H., Lü, Y., Lu, K., Li, S., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1595280 · Cited by 23

Extensive functional evaluation of exon 20 insertion mutations of EGFR

Hirose, T., Ikegami, M., Endo, M., Matsumoto, Y., Nakashima, Y., Mano, H., & Kohsaka, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.023 · Cited by 23

The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations

Tan, J., Hu, C., Deng, P., Wan, R., Cao, L., Li, M., Yang, H., Gu, Q., An, J., & Jiang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646577 · Cited by 23

Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review

Wu, L., Zhong, W., Li, A., Qiu, Z., Xie, R., Shi, H., & Lü, S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2823 · Cited by 23

Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study

Morán, T., Taus, Á., Arriola, E., Aguado, C., Dómine, M., Rueda, A. G., Calles, A., Cedrés, S., Viñolas, N., Isla, D., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.04.011 · Cited by 23

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations

Sa, H., Shi, Y., Ding, C., & Ma, K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04726-x · Cited by 21

Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations

Ma, C., Zhang, J., Tang, D., Ye, X., Li, J., Mu, N., Li, Z., Liu, R., Xiang, L., Huang, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00224 · Cited by 22

Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

Huang, C., Ju, J., Chiu, T.-H., Huang, A. C., Tung, P., Wang, C., Liu, C., Chung, F., Fang, Y., Guo, Y., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33821 · Cited by 21

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study

Lei, L., Wang, W., Zhu, Y., Li, J., Fang, Y., Wang, H., Zhuang, W., Zhang, Y.-B., Wang, L., Fang, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14277 · Cited by 20

PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer

Miyawaki, E., Murakami, H., Mori, K. P., Mamesaya, N., Kawamura, T., Kobayashi, H., Omori, S., Wakuda, K., Ono, A., Kenmotsu, H., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa033 · Cited by 20

Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing

Park, E., & Shim, H. S. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.305 · Cited by 20

Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India

Singh, V., Nambirajan, A., Malik, P. S., Thulkar, S. P., Pandey, R. M., Luthra, K., Arava, S., Ray, R., Mohan, A., & Jain, D. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.038 · Cited by 19

Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis

Lv, L., Liu, Z., Liu, Y., Zhang, W., Jiang, L., Li, T., Lu, X., Lei, X., Liang, W., & Lin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.519073 · Cited by 19

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study

Schuler, A., Huser, J., Schmid, S., Schär, S., Scherz, A., Gautschi, O. P., Mauti, L. A., von Briel, T., Waibel, C., Wannesson, L., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107427 · Cited by 19

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes

Xu, H., Yang, G., Li, W., Li, J., Hao, X., Xing, P., Yang, Y., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713483 · Cited by 19

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma

Xu, Z., Qin, F., Yuan, L., Wei, J., Sun, Y., Qin, J., Deng, K., Zheng, T., & Li, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.691915 · Cited by 16

Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma—An Indian Perspective of 212 Patients

Kaler, A. K., Patel, K., Patil, H., Tiwarekar, Y., Kulkarni, B. N., Hastak, M., Athikari, N., Rane, S., Nikam, A., Umarji, S., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20010758 · Cited by 17

Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report

Long, X., Tian, Q., & Lin, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s260157 · Cited by 16

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Park, S., Lee, S. Y., Kim, D.-J., Sim, Y. S., Ryu, J., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · BMC Cancer · doi:10.1186/s12885-020-07765-6 · Cited by 18

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model

Ikeuchi, H., Hirose, T., Ikegami, M., Takamochi, K., Suzuki, K., Mano, H., & Kohsaka, S. (2022) · Oncogene · doi:10.1038/s41388-022-02263-4 · Cited by 17

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

Li, H., Yang, G., Cai, Y., Li, J., Xu, H., Zhang, T., Zhou, L., Wang, Y., Wang, J., Hu, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919652 · Cited by 17

EGFR mutation status in a series of Turkish non-small cell lung cancer patients

Calibasi‐Kocal, G., Amirfallah, A., Sever, T., Ünal, O. Ü., Gürel, D., Öztop, İ., Ellıdokuz, H., & Başbınar, Y. (2020) · Biomedical Reports · doi:10.3892/br.2020.1308 · Cited by 16

Implementation of a molecular tumor board at a regional level to improve access to targeted therapy

Bourien, H., Lespagnol, A., Campillo‐Gimenez, B., Felten-Vinot, I., Metges, J., Corre, R., Lesimple, T., Maréchal, C. L., Boussemart, L., Kammerer‐Jacquet, S., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01661-6 · Cited by 14

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

Dafni, U. G., Soo, R. A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J., de Castro, J., Coate, L. E., Früh, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100507 · Cited by 14

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations

Shi, C., Zhang, C., Fu, Z., Liu, J., Zhou, Y., Cheng, B. H., Wang, C., Li, S., & Zhang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.007 · Cited by 13

Characteristics of TGFBR1–EGFR–CTNNB1–CDH1 Signaling Axis in Wnt-Regulated Invasion and Migration in Lung Cancer

Liu, R., Zhang, Y., Ding, Y., Zhang, S., & Pan, L. (2020) · Cell Transplantation · doi:10.1177/0963689720969167 · Cited by 13

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Wei, J., Meng, P., Terpstra, M. M., van Rijk, A. F., Tamminga, M., Scherpen, F. J. G., ter Elst, A., Alimohamed, M. Z., Johansson, L. F., Stigt, J. A., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00798-2 · Cited by 13

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters

Zeng, Y., Guo, T., Zhou, Y., Zhao, Y., Chu, L., Chu, X., Yang, X., Ni, J., & Zhu, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-09245-5 · Cited by 13

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors

Xu, H., Yang, G., Liu, R., Yang, Y., Li, W., Li, J., Hao, X., Xing, P., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976731 · Cited by 13

Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study

Qin, Y., Long, Y., Tang, Y., Tian, Y., Li, J., Duan, P., Luo, J., Yu, M., Li, Y., Zhou, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15769 · Cited by 12

D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer

Shi, Y., Li, C., Zhang, X., Peng, C., Sun, P., Zhang, Q., Wu, L., Ding, Y., Xie, D., Xu, Z., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae121 · Cited by 13

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors

Tsai, M., Hung, J., Lee, M., Kuo, C., Tsai, Y.-C., Tsai, Y., Liu, T., Yang, C., Huang, M., & Chong, I. (2018) · Cancers · doi:10.3390/cancers10110434 · Cited by 12

Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small‐cell lung cancer patients: A network meta‐analysis

Wu, Z., Chen, S., Du, X., Wu, Y., & Xie, X. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13281 · Cited by 14

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study

Lei, L., Wang, W., Zhu, Y., Li, J., Fang, Y., Wang, H., Zhuang, W., Zhang, Y.-B., Wang, L., Fang, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2652 · Cited by 12

Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice

Yamada, Y., Tamura, T., Yamamoto, Y., Ichimura, H., Hayashihara, K., Saito, T., Yamada, H., Endo, T., Nakamura, R., Inage, Y., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14592 · Cited by 11

miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR

Wang, K., Xu, K., Leng, X., Han, Y., & Fang, Q. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820945807 · Cited by 11

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Gao, X., Wei, X., Zheng, M.-Y., Chen, Z.-H., Zhang, X., Zhong, W., Yang, J., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1630 · Cited by 11

Inhibiting Two Cellular Mutant Epidermal Growth Factor Receptor Tyrosine Kinases By Addressing Computationally Assessed Crystal Ligand Pockets

Lee, J.-H., Lin, W., Wen, T., Wang, C., & Lin, Y. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0525 · Cited by 10

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

Cheng, W., Lin, C., Liao, W., Lin, Y.-C., Chen, C., Chen, H.-J., Tu, C., & Hsia, T. (2024) · BMC Cancer · doi:10.1186/s12885-024-11956-w · Cited by 14

Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer

Haddish‐Berhane, N., Su, Y., Russu, A., Thayu, M., Knoblauch, R. E., Mehta, J., Xie, J., Gibbs, E., Sun, Y., & Zhou, H. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3064 · Cited by 10

Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients

Scodes, S., & Cappuzzo, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1746646 · Cited by 10

Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Wei, L., Lao, Y., Fu, T., Xie, Z., Wang, Y., Yang, T., Huang, L., Liu, J., Shu, M., Tian, T., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.04.007 · Cited by 9

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors

Yang, G., Yang, Y., Hu, J., Xu, H., Zhang, S., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.984503 · Cited by 11

Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer

Taniguchi, Y., Takeda, M., Tamiya, A., Kasai, T., & Atagi, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy401 · Cited by 9

Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

Kim, Y.-J., Oremus, M., Chen, H., McFarlane, T., Fearon, D. O., & Horton, S. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0173 · Cited by 8

Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report

He, S., Lin, Q., Chen, J., Yu, G., Zhang, J., & Shen, D. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i6.1329 · Cited by 8

The predictive value of uncommon EGFR mutation in patients with non-small-cell lung cancer.

Tu, H., Ke, E., Sun, Y., Zheng, M.-Y., Yang, J., Wang, Z., Wu, S.-P., Su, J., Zhang, X., Bai, X., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9028 · Cited by 1

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes

John, T., Taylor, A., Wang, H., Eichinger, C. S., Freeman, C. S., & Ahn, M. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2021.102080 · Cited by 80

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Chantharasamee, J., Poungvarin, N., Danchaivijitr, P., & Techawatanawanna, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-5913-9 · Cited by 21

Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations

Zhang, Y., Department of Medical Oncology, N. C. C. H., Wang, Z., Hao, X., Hu, X., Wang, H., Wang, Y., Ying, J., Department of Pathology, B. H., & Department of Pathology, N. C. C. H. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.01.03 · Cited by 35

Clinicopathological Characteristics and Therapeutic Effect of Patients with Non-small Cell Lung Cancer and Uncommon EGFR Mutations

Wenjia, S., 岳君秋, & Wang, M. (2023) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3971/j.issn.1000-8578.2023.23.0431